LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Other Non-Current Liabilities

Last Annual Value

1.34M

3-Year CAGR

-63%

5-Year CAGR

-45%

10-Year CAGR

-26%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Other Non-Current Liabilities

LBRX · NASDAQ
CompanyOther Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.34M
-74.1%N/AN/A 
0.00
N/AN/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
0.00
N/AN/AN/A
2.81M
16.1%N/A21.7%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
32.47M
-7.7%-20.8%N/A
0.00
N/AN/AN/A
517.00K
-47.9%-35.3%N/A
941.00K
25.9%N/AN/A
410.00K
17.5%17.6%N/A
1.06M
-28.8%67.7%13.2%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
1.48M
12.0%76.3%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95